Instil bio inc
TIL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
TIL 近期報酬表現
0.66%
Instil bio inc
1.95%
同產業平均
0.87%
S&P500
與 TIL 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BFRG | Bullfrog ai holdings, inc. | - | 2 分 | 2 分 | - | 1 分 | |
CVKD | Cadrenal therapeutics inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
VXRT | Vaxart inc | 4 分 | 2 分 | 1 分 | 1 分 | 1 分 | |
ME | 23andme holding co. | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
QSI | Quantum-si inc | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 |
- BFRG Bullfrog ai holdings, inc.價值 -趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
TIL 公司資訊
Instil Bio Inc. Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. It is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.